| Zhang, Lei |
NCT04490590: A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma |
|
|
| Recruiting | 4 | 30 | RoW | Chidamide+ Etoposide | Mingzhi Zhang | NK/T-Cell Lymphoma | 10/20 | 10/21 | | |
NCT04518475: Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults |
|
|
| Recruiting | 4 | 224 | RoW | eltrombopag combining rituximab, TPO-R agonist & anti-CD20 antibody, eltrombopag, TPO-R agonist | Institute of Hematology & Blood Diseases Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, Nantong University | Primary Immune Thrombocytopenia (ITP) | 02/22 | 08/22 | | |
NCT05585151: High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study |
|
|
| Recruiting | 4 | 200 | RoW | Evolocumab 140 MG/ML, Intensive statin treatment | Wuhan Union Hospital, China | Cerebral Atherosclerosis | 04/24 | 10/24 | | |
NCT05718856: TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 4 | 166 | RoW | TPO-RAs, TPO-R agonists, TPO-RAs combining anti-CD 20 monoclonal antibody, TPO-R agonist & anti-CD 20 monoclonal antibody | Institute of Hematology & Blood Diseases Hospital, China, Beijing Children's Hospital, Tianjin People's Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University | Primary Immune Thrombocytopenia (ITP) | 05/25 | 11/25 | | |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT05888870: ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor |
|
|
| Recruiting | 4 | 50 | RoW | SCT800 and Daratumumab, Immune tolerance induction combine anti-CD38, SCT800, Immune tolerance induction only | Institute of Hematology & Blood Diseases Hospital, China, Sinocelltech Ltd. | Hemophilia A With Inhibitor | 12/26 | 12/26 | | |
AHA2023, NCT05849740: An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A |
|
|
| Recruiting | 4 | 10 | RoW | Daratumumab and corticosteroid treatment, Intervention arm | Institute of Hematology & Blood Diseases Hospital | Acquired Hemophilia | 04/27 | 10/27 | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT05487976: Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor |
|
|
| Recruiting | 3 | 50 | RoW | Recombinant human activated coagulation factor VII for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophilia A, Hemophilia B | 04/23 | 04/23 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
NCT06297655: A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A |
|
|
| Not yet recruiting | 3 | 60 | RoW | Recombinant human activated coagulation factor VIII for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Hemophilia A | 04/25 | 04/25 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
NCT05203679: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug |
|
|
| Active, not recruiting | 3 | 32 | RoW | Single dose intravenous injection of BBM-H901 | Shanghai Belief-Delivery BioMed Co., Ltd | Hemophilia B | 04/24 | 06/28 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT04915482: TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies |
|
|
| Recruiting | 2/3 | 94 | RoW | Combined use of TPO-RAs with low-dose anti-CD20 antibody, The best available therapy | Institute of Hematology & Blood Diseases Hospital, China | Immune Thrombocytopenia (ITP), Autoantibodies, Evan Syndrome, Connective Tissue Diseases | 01/25 | 02/25 | | |
NCT04696939: Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients |
|
|
| Not yet recruiting | 2 | 100 | RoW | Atezolizumab, Carboplatin, Etoposide | Shanghai Pulmonary Hospital, Shanghai, China | Small-cell Lung Cancer, Neoadjuvant Therapy | 08/22 | 10/23 | | |
NCT04226950: Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia |
|
|
| Recruiting | 2 | 40 | RoW | Recombinant Interferon Alpha, Pegylated interferon alfa-2b | Institute of Hematology & Blood Diseases Hospital, China | Essential Thrombocytopenia | 10/24 | 11/24 | | |
NCT05619926: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor |
|
|
| Completed | 2 | 32 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Novikang Medical Technology Co., LTD | Hemophilia | 08/23 | 08/23 | | |
NCT06168851: Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 2 | 20 | RoW | Anti-CD38 antibody Injection | Institute of Hematology & Blood Diseases Hospital, China, Beijing Children's Hospital, Tianjin Children's Hospital | Immune Thrombocytopenia, Treatment | 12/25 | 12/25 | | |
NCT05199909: Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia |
|
|
| Recruiting | 2 | 10 | RoW | zanubrutinib, The treatment of zanubrutinib | Zhang Lei, MD | Antiphospholipid Syndrome, Thrombocytopenia, Treatment | 12/23 | 06/24 | | |
NCT05214391: A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 30 | RoW | Zanubrutinib, The treatment of zanubrutinib | Zhang Lei | Immune Thrombocytopenia, Treatment | 12/23 | 06/24 | | |
NCT06199089: A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia |
|
|
| Active, not recruiting | 2 | 45 | RoW | CM313 Injection, Placebo Injection | Institute of Hematology & Blood Diseases Hospital, China, Tianjin People's Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, North China University of Science and Technology Affiliated Hospital | Immune Thrombocytopenia, Treatment | 11/24 | 12/24 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT04962958: Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery |
|
|
| Not yet recruiting | 2 | 30 | RoW | Hepatic arterial infusion chemotherapy, HAIC, Folfox Protocol, Oxaliplatin , fluorouracil, and leucovorin, Donafenib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Huashan Hospital, The Second Affiliated Hospital of Harbin Medical University | Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms, Antineoplastic Agents, Donafenib, Fluorouracil, Oxaliplatin, Antimetabolites | 03/24 | 08/24 | | |
NCT06281327: Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 60 | RoW | Avatrombopag | Institute of Hematology & Blood Diseases Hospital, China, Henan Cancer Hospital, Tianjin Medical University Second Hospital, Tianjin Children's Hospital, The Second Affiliated Hospital of Kunming Medical University | Immune Thrombocytopenia, Treatment | 12/25 | 12/25 | | |
| Recruiting | 2 | 25 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 02/25 | 02/25 | | |
NCT05218226: Avatrombopag for Chemotherapy-induced Thrombocytopenia |
|
|
| Recruiting | 2 | 50 | RoW | Avatrombopag | Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Second Hospital, Tianjin Third Central Hospital, Tianjin People's Hospital, Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University | Chemotherapy-induced Thrombocytopenia, Avatrombopag | 03/24 | 12/24 | | |
NCT05236582: Herombopag for Chemotherapy-induced Thrombocytopenia |
|
|
| Recruiting | 2 | 50 | RoW | Herombopag | Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Second Hospital, Tianjin Third Central Hospital, Tianjin People's Hospital, Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University | Chemotherapy-induced Thrombocytopenia, Herombopag | 03/24 | 12/24 | | |
NCT06287567: Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 2 | 17 | RoW | Lusutrombopag Oral Tablet, MULPLETA®, S-888711 | Institute of Hematology & Blood Diseases Hospital, China | Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | 09/24 | 11/24 | | |
NCT06658834: A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP |
|
|
| Recruiting | 2 | 129 | RoW | Dexamethasone Combined with romiplostim N01, Dexamethasone monotherapy | Institute of Hematology & Blood Diseases Hospital, China, The Second Affiliated Hospital of Kunming Medical University, Weifang People's Hospital, Shenzhen Second People's Hospital, The Affiliated Hospital of Qingdao University, Changzhi Medical College, Affiliated Hospital of Nantong University, The First People's Hospital of Yunnan, First Affiliated Hospital Bengbu Medical College, Suining Central Hospital, The Second Affiliated Hospital of Dalian Medical University, Affiliated Hospital of North China University of Science and Technology, Guizhou Provincial People's Hospital | Primary Immune Thrombocytopenia | 06/25 | 08/26 | | |
| Recruiting | 2 | 20 | RoW | CM313 Injection | Institute of Hematology & Blood Diseases Hospital | Immune Thrombocytopenia, Treatment | 06/24 | 12/24 | | |
NCT04993885: Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies |
|
|
| Recruiting | 2 | 52 | RoW | Avatrombopag | Institute of Hematology & Blood Diseases Hospital, China | Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases | 07/24 | 09/24 | | |
NCT06552429: Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET |
|
|
| Recruiting | 2 | 27 | RoW | Peginterferon α-2b injection | Xiamen Amoytop Biotech Co., Ltd. | Essential Thrombocythemia | 09/25 | 09/27 | | |
CUSIS-FS-Pilot, NCT06626568: Comparison of Ultrasound-Guided Subacromial Vs. Systemic Steroid Injections for Frozen Shoulder: a Multicenter Pilot Study |
|
|
| Recruiting | 2 | 40 | RoW | Compound betamethasone Injection(Gluteal muscle injection), Compound betamethasone Injection(Subacromial Ultrasound Guided injection), Normal Saline as Placebo (ultrasound-guided subacromial injection), Normal Saline as Placebo (gluteal muscle inection), home exercise | Second Affiliated Hospital, School of Medicine, Zhejiang University | Frozen Shoulder | 09/25 | 09/25 | | |
NCT05913661: Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Pemigatinib, Pemazyre, PD-1 Inhibitors, Sintilimab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Jinan University, Shenzhen University General Hospital | Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor, First-line Treatment | 11/24 | 11/24 | | |
NCT06594146: Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) |
|
|
| Not yet recruiting | 2 | 60 | NA | CM313 injection, placebo | Keymed Biosciences Co.Ltd | Primary Immune Thrombocytopenia | 12/25 | 12/25 | | |
NCT06799611: An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 20 | RoW | CM336 Injection | Institute of Hematology & Blood Diseases Hospital, China | Immune Thrombocytopenia (ITP), Treatment | 01/26 | 01/27 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT05395507: Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia |
|
|
| Recruiting | 2 | 194 | RoW | Recombinant Interferon Alpha, Pegylated interferon alfa-2b | Institute of Hematology & Blood Diseases Hospital, China | Essential Thrombocytopenia | 03/25 | 06/25 | | |
NCT05983952: Anti-CD38 Antibody Treating APS With Thrombocytopenia |
|
|
| Recruiting | 2 | 10 | RoW | Anti-CD38 antibody Injection | Institute of Hematology & Blood Diseases Hospital | Antiphospholipid Syndrome, Thrombocytopenia | 08/25 | 08/25 | | |
2023CD20ITP, NCT05995054: A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 110 | RoW | Obinutuzumab Injection [Gazyva] | Institute of Hematology & Blood Diseases Hospital | Immune Thrombocytopenia, Treatment | 08/25 | 08/26 | | |
| Recruiting | 2 | 10 | RoW | Anti-CD38 antibody Injection | Institute of Hematology & Blood Diseases Hospital, China | Evan Syndrome, Treatment | 08/25 | 08/25 | | |
NCT06094881: A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 2 | 60 | RoW | Obinutuzumab Injection [Gazyva] | Institute of Hematology & Blood Diseases Hospital, China | Immune Thrombocytopenia, Treatment | 11/25 | 11/26 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
PV, NCT05870475: Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant |
|
|
| Recruiting | 2 | 94 | RoW | Ruxolitinib, RUX, Pegylated interferon α-2b, PEG IFNα-2b | Institute of Hematology & Blood Diseases Hospital, China | Polycythemia Vera | 03/28 | 05/28 | | |
NCT05027230: A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor |
|
|
| Completed | 1/2 | 77 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 07/23 | 07/23 | | |
NCT05641610: A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients |
|
|
| Not yet recruiting | 1/2 | 21 | RoW | ZS801 | Institute of Hematology & Blood Diseases Hospital | Hemophilia B | 12/24 | 12/28 | | |
NCT05441553: A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients |
|
|
| Not yet recruiting | 1/2 | 26 | RoW | VGB-R04 | Shanghai Vitalgen BioPharma Co., Ltd. | Hemophilia B | 01/25 | 01/25 | | |
NCT06776510: A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia |
|
|
| Not yet recruiting | 1/2 | 20 | RoW | nicotinamide adenine dinucleotid/nicotinamide mononucleotide, Coenzyme I for Injection（NAD+）/NMN | Institute of Hematology & Blood Diseases Hospital, China | Immune Thrombocytopenia, Treatment | 06/25 | 06/25 | | |
NCT05924997: Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 52 | RoW | adebrelimab, camrelizumab plus apatinib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Advanced Hepatocellular Carcinoma | 06/25 | 06/26 | | |
NCT06111638: Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs |
|
|
| Recruiting | 1/2 | 12 | RoW | Single dose intravenous injection of BBM-H803 | Shanghai Belief-Delivery BioMed Co., Ltd, Shanghai MYGT Biopharmaceutical LLC | Hemophilia A | 06/26 | 06/30 | | |
NCT04747964: A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor |
|
|
| Completed | 1 | 16 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 04/21 | 04/21 | | |
| Not yet recruiting | 1 | 8 | RoW | Single dose intravenous injection of BBM 002 | Institute of Hematology & Blood Diseases Hospital | Hemophilia A | 09/23 | 09/27 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT05562882: A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia |
|
|
| Not yet recruiting | 1 | 20 | NA | Daratumumab Injection, Darzalex | Institute of Hematology & Blood Diseases Hospital | Immune Thrombocytopenia | 12/23 | 05/24 | | |
NCT06238908: Safety and Efficacy Study of NGGT003 in Hemophilia A Patients |
|
|
| Not yet recruiting | 1 | 6 | RoW | NGGT003 | Institute of Hematology & Blood Diseases Hospital, China | Hemophilia A | 01/26 | 01/30 | | |
| Recruiting | 1 | 108 | RoW | GLB-001, GLB-C183-A-2 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy | 12/26 | 12/27 | | |
NCT05152732: Safety and Tolerability of VGB-R04 in Patients With Haemophilia B |
|
|
| Recruiting | 1 | 3 | RoW | VGB-R04 | Institute of Hematology & Blood Diseases Hospital | Hemophilia B | 03/25 | 12/25 | | |
NCT05709288: Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old |
|
|
| Recruiting | 1 | 9 | RoW | BBM-H901 | Institute of Hematology & Blood Diseases Hospital, China | Hemophilia B | 06/35 | 11/35 | | |
NCT06379230: A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) |
|
|
| Recruiting | N/A | 2000 | RoW | This study is purely descriptive study. | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Neurofibromatosis 1, Plexiform Neurofibroma | 12/22 | 02/25 | | |
NCT03998059: Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients |
|
|
| Recruiting | N/A | 50 | RoW | splenectomy | Zhang Lei | Thrombocytopenia, Splenectomy | 01/22 | 07/22 | | |
| Not yet recruiting | N/A | 60 | RoW | Endostar, S1 | Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university | Radiotherapy Side Effect | 01/22 | 01/23 | | |
NCT04014166: Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia |
|
|
| Active, not recruiting | N/A | 18 | RoW | Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) | Institute of Hematology & Blood Diseases Hospital | Thrombocytopenia, Mesenchymal Stem Cells | 02/23 | 06/23 | | |
NCT05217459: The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease |
|
|
| Completed | N/A | 128 | RoW | Self-expanding intracranial drug stent system | Sinomed Neurovita Technology Inc., Changhai Hospital | Intracranial Arterial Diseases, Stent Restenosis, Percutaneous Transluminal Angioplasty | 08/23 | 03/24 | | |
ITP, NCT04890041: TPO-RA in Primary Immune Thrombocytopenia () in Patients Older Than 14 Years |
|
|
| Recruiting | N/A | 100 | RoW | TPO-RA, TPO-RAs | Institute of Hematology & Blood Diseases Hospital | Primary Immune Thrombocytopenic Purpura | 11/23 | 12/23 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
TTV, NCT05727709: Dynamic Changes of Torquetenovirus () Load in Chinese Renal Transplant Recipients |
|
|
| Recruiting | N/A | 220 | RoW | | Tongji Hospital, Anapure BioScience, Caibo MedTech, SKM BioTech | Kidney Transplant Rejection, Kidney Transplant Infection, Virus, Immunosuppression | 12/23 | 06/24 | | |
| Recruiting | N/A | 96 | RoW | Modified ERAS protocol, routine protocol | Xuanwu Hospital, Beijing | Lumbar Spondylosis, Lumbar Spinal Stenosis, Lumbar Disc Herniation | 08/24 | 04/25 | | |
NCT05523128: The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients. |
|
|
| Not yet recruiting | N/A | 6 | RoW | ZS802 | Institute of Hematology & Blood Diseases Hospital | Hemophilia A | 10/24 | 10/24 | | |
NCT05630651: The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. |
|
|
| Not yet recruiting | N/A | 6 | RoW | ZS801 | Institute of Hematology & Blood Diseases Hospital | Hemophilia B | 12/24 | 12/28 | | |
NCT05872607: The Quantitative Study of the Habenula Based on Multi-channel Cascaded Neural Network and the Establishment of the Prediction Model of the Curative Effect in Patients With Depression |
|
|
| Recruiting | N/A | 300 | RoW | | The First Hospital of Jilin University | Depression | 12/24 | 12/24 | | |
NCT06749678: Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 84 | RoW | Prehabilitation, Routine nursing measures | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Advanced Hepatocellular Carcinoma (HCC), Prehabilitation | 01/27 | 06/27 | | |
| Not yet recruiting | N/A | 500 | US | Hospital-Linked Violence Intervention Program, Mobile Community Event Support, Unrestricted Cash Assistance | University of Mississippi Medical Center, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD) | Gun Shot Wound | 12/27 | 06/28 | | |
| Completed | N/A | 34 | US, RoW | SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System | Boston Scientific Corporation | Pancreatic Diseases, Bile Duct Diseases, Hepatic Disease | 12/24 | 01/25 | | |
NCT04456985: Effect of Preoperative Intervention With Folic Acid and Vitamin B12 on Postoperative Neurobehavioral Changes in Children |
|
|
| Recruiting | N/A | 360 | RoW | Folic acid and vitamin B12, brown sugar aqueous | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Delirium | 06/25 | 06/25 | | |
NCT04765605: Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study) |
|
|
| Active, not recruiting | N/A | 120 | RoW | WeFlow-Tbranch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Type B Aortic Dissection | 12/26 | 12/26 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Active, not recruiting | N/A | 501 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
STERILE, NCT05390216: Impact of Partial Capsule Decortication on Device-related Infection in Patients Receiving Cardiac Implantable Electronic Device Replacement |
|
|
| Active, not recruiting | N/A | 1016 | RoW | Partial capsule decortication | Shanghai Zhongshan Hospital | Pacemaker Complication, Infections | 05/26 | 05/30 | | |
NCT06107582: Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | N/A | 500 | RoW | data collection | Institute of Hematology & Blood Diseases Hospital, China, Beijing Children's Hospital, Tianjin People's Hospital, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, The Second Affiliated Hospital of Kunming Medical University | Primary Immune Thrombocytopenia | 12/26 | 12/36 | | |
| Recruiting | N/A | 12 | RoW | Injection of GS001 | Institute of Hematology & Blood Diseases Hospital | Hemophilia A, Gene Therapy | 07/28 | 07/28 | | |
NCT04937283: Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm |
|
|
| Recruiting | N/A | 690 | RoW | Segmentectomy with systemic lymph node dissection, Lobectomy with hilar and mediastinal lymph node dissection | Shanghai Pulmonary Hospital, Shanghai, China | Lung Adenocarcinoma | 12/28 | 12/28 | | |
| Active, not recruiting | N/A | 10 | RoW | Single dose intravenous injection of BBM-H901 | Institute of Hematology & Blood Diseases Hospital, China, East China University of Science and Technology | Hemophilia B | 12/39 | 12/39 | | |
NCT05442528: Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study |
|
|
| Not yet recruiting | N/A | 20 | NA | | Shanghai Vitalgen BioPharma Co., Ltd. | Hemophilia B | 12/24 | 12/24 | | |
| Recruiting | N/A | 50000 | RoW | No additional intervention will be administered. | Peking Union Medical College Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Tianjin First Central Hospital, Hebei Medical University Third Hospital, Dalian Hospital of Chinese Traditional and Western Medicine, The Second Affiliated Hospital of Harbin Medical University, Peking University Third Hospital, Beijing Shijingshan Hospital, The Second Medical Center of The General Hospital of the People's Liberation Army, Huamei hospital, University of Chinese Academy of Sciences, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, Ruijin Hospital, The First People's Hospital of Changzhou, Affiliated Hospital of Nantong University, Nantong First People's Hospital, Shanghai Changzheng Hospital, Wuhan Union Hospital, China, Central South University, Guangdong Provincial People's Hospital, Nanfang Hospital of Southern Medical University, Lunjiao Hospital of Shunde Foshan, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou Second Hospital, Second Affiliated Hospital of Guangzhou Medical University, Shenzhen Second People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Sichuan Provincial People's Hospital, West China Fourth Hospital, Sichuan Province Orthopedic Hospital, The Second Affiliated Hospital of Chongqing Medical University, Daping Hospital, Army Medical Center of PLA, Guizhou Provincial Orthopedics Hospital, First Affiliated Hospital Xi'an Jiaotong University, Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, The First Affiliated Hospital of Zhengzhou University | Osteoporosis, Osteoporotic Fractures | 12/24 | 12/24 | | |
| Chen, Yunfei |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT04600960: Eltrombopag for Chemotherapy-induced Thrombocytopenia |
|
|
| Recruiting | 2 | 50 | RoW | Eltrombopag | Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Second Hospital, Tianjin Third Central Hospital, Tianjin People's Hospital, Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University | Chemotherapy-induced Thrombocytopenia, Eltrombopag | 03/23 | 12/23 | | |
NCT06168851: Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP) |
|
|
| Recruiting | 2 | 20 | RoW | Anti-CD38 antibody Injection | Institute of Hematology & Blood Diseases Hospital, China, Beijing Children's Hospital, Tianjin Children's Hospital | Immune Thrombocytopenia, Treatment | 12/25 | 12/25 | | |
NCT05199909: Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia |
|
|
| Recruiting | 2 | 10 | RoW | zanubrutinib, The treatment of zanubrutinib | Zhang Lei, MD | Antiphospholipid Syndrome, Thrombocytopenia, Treatment | 12/23 | 06/24 | | |
NCT05214391: A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 30 | RoW | Zanubrutinib, The treatment of zanubrutinib | Zhang Lei | Immune Thrombocytopenia, Treatment | 12/23 | 06/24 | | |
NCT06199089: A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia |
|
|
| Active, not recruiting | 2 | 45 | RoW | CM313 Injection, Placebo Injection | Institute of Hematology & Blood Diseases Hospital, China, Tianjin People's Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, North China University of Science and Technology Affiliated Hospital | Immune Thrombocytopenia, Treatment | 11/24 | 12/24 | | |
NCT05218226: Avatrombopag for Chemotherapy-induced Thrombocytopenia |
|
|
| Recruiting | 2 | 50 | RoW | Avatrombopag | Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Second Hospital, Tianjin Third Central Hospital, Tianjin People's Hospital, Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University | Chemotherapy-induced Thrombocytopenia, Avatrombopag | 03/24 | 12/24 | | |
NCT05236582: Herombopag for Chemotherapy-induced Thrombocytopenia |
|
|
| Recruiting | 2 | 50 | RoW | Herombopag | Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Second Hospital, Tianjin Third Central Hospital, Tianjin People's Hospital, Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University | Chemotherapy-induced Thrombocytopenia, Herombopag | 03/24 | 12/24 | | |
| Recruiting | 2 | 20 | RoW | CM313 Injection | Institute of Hematology & Blood Diseases Hospital | Immune Thrombocytopenia, Treatment | 06/24 | 12/24 | | |
NCT06799611: An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 20 | RoW | CM336 Injection | Institute of Hematology & Blood Diseases Hospital, China | Immune Thrombocytopenia (ITP), Treatment | 01/26 | 01/27 | | |
NCT05983952: Anti-CD38 Antibody Treating APS With Thrombocytopenia |
|
|
| Recruiting | 2 | 10 | RoW | Anti-CD38 antibody Injection | Institute of Hematology & Blood Diseases Hospital | Antiphospholipid Syndrome, Thrombocytopenia | 08/25 | 08/25 | | |
2023CD20ITP, NCT05995054: A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 110 | RoW | Obinutuzumab Injection [Gazyva] | Institute of Hematology & Blood Diseases Hospital | Immune Thrombocytopenia, Treatment | 08/25 | 08/26 | | |
